Ipilimumab-induced hypophysitis: early Australian experience

Med J Aust. 2014 Aug 18;201(4):198-9. doi: 10.5694/mja14.00803.

Authors

Sunita M C De Sousa¹, Georgina V Long², Katherine T Tonks³

Affiliations

¹ Department of Endocrinology, St Vincent's Hospital, Sydney, NSW, Australia. s.desousa@garvan.org.au.
² Melanoma Institute Australia, Sydney, NSW, Australia.
³ Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, NSW, Australia.

PMID: 25164840
DOI: 10.5694/mja14.00803

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Australia
Disease Progression
Glucocorticoids / therapeutic use
Humans
Hypopituitarism / chemically induced*
Hypopituitarism / drug therapy
Hypopituitarism / immunology
Hypopituitarism / pathology*
Ipilimumab
Male
Melanoma / drug therapy
Melanoma / secondary
Middle Aged
Prednisolone / therapeutic use
Skin Neoplasms / drug therapy
Skin Neoplasms / secondary

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Glucocorticoids
Ipilimumab
Prednisolone